The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.
A 25-year-old male experienced increased testosterone and estradiol levels after starting finasteride for hair loss, leading his doctor to suggest a testicular ultrasound as a precaution. The user questions the necessity of the ultrasound, considering it potentially excessive, while others suggest it could be a useful precaution to rule out any issues.
Finasteride can affect sperm quality, but fertility usually returns after stopping it, as shown by a user who conceived four months after discontinuation. Some users successfully conceive while on finasteride, though some prefer to pause its use to minimize risks.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
The user reports significant hair density improvement after 8.5 months of using finasteride, with no side effects except for initially watery semen. They also mention increased sex drive, which they attribute to finasteride, and regret not starting the treatment earlier due to fear of side effects.
The conversation discusses the use of Minoxidil and finasteride for hair loss and explores the potential of Geranium sibiricum extract as a safer alternative. It highlights the difficulty in finding this specific extract and suggests considering other plants with similar compounds, like Indian gooseberry.
The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.
The user experienced hair regrowth after one year on 1mg finasteride daily and a hair transplant in the frontal area, with improved density in the rear and mid-scalp. Some replies express skepticism and suggest the title should include mention of the hair transplant.
The user shared progress pictures showing significant improvement in hair loss after using finasteride, RU58841, and undergoing a 3000 graft hair transplant. They plan to get another transplant due to remaining thin areas.
Androgenetic alopecia is affected by scalp DHT levels, not sensitivity, with treatments like finasteride and dutasteride aiming to optimize these levels. Personalized DHT management is crucial for effective hair growth.
Finasteride can cause gynecomastia due to hormonal imbalances. Management includes consulting an endocrinologist and using aromatase inhibitors like anastrozole or supplements like DIM and zinc.
A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
A 33-year-old male is experiencing thinning at the temples and hairline, with increased shedding over the past year. The user suspects androgenetic alopecia (AGA) despite AI suggesting a maturing hairline.
A user is seeking advice on increasing graft survivability after a hair transplant, mentioning PRP, Mesotherapy, Stem Cell injections, and considering L-Arginine before starting Minoxidil. They are looking for ways to support blood flow before applying Minoxidil.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly credits a person for the potential success of a treatment called GT20029.
A user shared their experience with a second hair transplant by Dr. Gokhan Gur, focusing on the midscalp and crown with 1849 grafts. Their current treatment includes dutasteride, finasteride, oral and topical minoxidil, and Nizoral shampoo.
The potential hair regrowth benefits of ASC-J9, a synthetic modified version of curcumin that is said to be more effective than Minoxidil and Finasteride. Reports from users suggest good thickening and temple regrowth with topical use at 0.025% concentration.
Isoflavones from soybeans may help limit estrogen's effects on the body, potentially preventing gyno. However, surgery is the only way to remove gland enlargement.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
A user named "Redbone2222" shares their positive experience with a hair transplant procedure of 2500-3000 grafts, along with the use of 1mg finasteride daily and 5% topical minoxidil. They express satisfaction with the results and believe that finasteride has been more effective for them than minoxidil.
The conversation discusses using GHK Cu + AHK Cu peptides combined with topical dutasteride and minoxidil for hair regrowth. It mentions negative side effects of finasteride and promotes a specific copper peptide serum.
Hair loss is influenced by multiple genetic factors, not just maternal lineage. Treatments like finasteride, minoxidil, and nizoral are suggested if male pattern baldness progresses.
The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.
Finasteride significantly increased testosterone levels for the user, with no major side effects except watery semen, which was resolved with zinc supplements. The user's hairline stopped receding and slightly improved.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.